11/25
09:08 am
fate
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
fate
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Neutral
Report
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
11/13
08:30 am
fate
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
11/4
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/4
12:09 pm
fate
Fate Therapeutics (NASDAQ:FATE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Fate Therapeutics (NASDAQ:FATE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.
10/31
07:19 am
fate
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
Medium
Report
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
10/27
08:43 am
fate
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock.
High
Report
Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $7.00 price target on the stock.
10/27
08:06 am
fate
Fate Therapeutics (NASDAQ:FATE) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
High
Report
Fate Therapeutics (NASDAQ:FATE) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
10/26
11:30 am
fate
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Medium
Report
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
10/14
08:18 am
fate
Fate Therapeutics appoints new CFO to support autoimmune program expansion [Seeking Alpha]
Medium
Report
Fate Therapeutics appoints new CFO to support autoimmune program expansion [Seeking Alpha]
10/14
08:00 am
fate
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Medium
Report
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
10/10
10:56 am
fate
CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight Report 2026 - First CD276 Therapy Approval Anticipated by 2028 [Yahoo! Finance]
Medium
Report
CD276 Targeted Therapies Clinical Trials & Market Opportunity Insight Report 2026 - First CD276 Therapy Approval Anticipated by 2028 [Yahoo! Finance]
10/4
10:37 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year [Yahoo! Finance]
High
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners may be pleased with recent gains after 62% loss over the past year [Yahoo! Finance]
10/2
04:11 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Neutral
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/2
04:01 pm
fate
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)